On the 12th, GlycoNex announced that it has signed a manufacturing agreement with UK-based contract development and manufacturing organization Sterling Pharma Solutions. Under this agreement, Sterling’s specialized Antibody-Drug Conjugate (ADC) division will manufacture GlycoNex’s GNX102-ADC in preparation for its upcoming Phase I human clinical trial.
Read more